CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 86 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q1 2020. The put-call ratio across all filers is 0.18 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $8,134,000 | +9.7% | 68,699 | +9.5% | 0.00% | 0.0% |
| Q4 2020 | $7,413,000 | +118.0% | 62,765 | +105.1% | 0.00% | 0.0% |
| Q3 2020 | $3,401,000 | +7.7% | 30,607 | -1.0% | 0.00% | 0.0% |
| Q2 2020 | $3,158,000 | +4.5% | 30,916 | +10.4% | 0.00% | 0.0% |
| Q1 2020 | $3,022,000 | -53.6% | 28,002 | -50.0% | 0.00% | 0.0% |
| Q4 2019 | $6,518,000 | +103.9% | 56,012 | +100.5% | 0.00% | 0.0% |
| Q3 2019 | $3,197,000 | +19.9% | 27,934 | -0.2% | 0.00% | 0.0% |
| Q2 2019 | $2,667,000 | +13.2% | 27,987 | +8.4% | 0.00% | 0.0% |
| Q1 2019 | $2,356,000 | -36.4% | 25,823 | -47.1% | 0.00% | 0.0% |
| Q4 2018 | $3,706,000 | +98.6% | 48,832 | +109.3% | 0.00% | 0.0% |
| Q3 2018 | $1,866,000 | -18.8% | 23,328 | +0.8% | 0.00% | 0.0% |
| Q2 2018 | $2,299,000 | +60.1% | 23,152 | +30.5% | 0.00% | – |
| Q1 2018 | $1,436,000 | +4.4% | 17,740 | +1.6% | 0.00% | – |
| Q4 2017 | $1,375,000 | – | 17,460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kite Lake Capital Management (UK) LLP | 207,382 | $24,135,000 | 76.46% |
| Maso Capital Partners Ltd | 539,597 | $62,798,000 | 20.20% |
| York Capital Management Global Advisors, LLC | 1,102,163 | $128,270,000 | 7.40% |
| HHLR ADVISORS, LTD. | 2,751,200 | $320,185,000 | 3.99% |
| Dalton Investments, Inc. | 15,551 | $1,810,000 | 1.14% |
| Athos Capital Ltd | 8,290 | $965,000 | 0.96% |
| Myriad Asset Management Ltd. | 67,019 | $7,799,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 990,000 | $115,216,000 | 0.75% |
| OXFORD ASSET MANAGEMENT LLP | 211,646 | $24,631,000 | 0.68% |
| AGF Investments America Inc. | 12,230 | $1,423,000 | 0.47% |